Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
65.50    -0.50 (-0.76%)
Bid:
65.00
Ask:
66.00
Spread: 1.00 (1.538%)
Market Cap: £79.80m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

Director/PDMR Shareholding

4 Jun 2026 07:00

RNS Number : 9188G
Venture Life Group PLC
04 June 2026
Ā 

4 June 2026

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Company")

Director/PDMR Shareholding

Venture LifeĀ (AIM: VLG), a recognised leader in proactive longevity, health innovation and global commercialisation within the global consumer healthcare sector, announces that Paul McGreevy, Non-Executive Chairman, purchased 88,273 ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary Shares") on 3 June 2026 at a volume-weighted average price of 62.3 pence per Ordinary Share.

Following the purchase, Mr McGreevy beneficially holds 1,052,098 Ordinary Shares representing approximately 0.82 per cent. of the Company's issued share capital.

Ā 

For further information, please contact:

Ā 

Venture Life Group PLC

+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

Ā 

Cavendish Capital Markets Limited (Nomad and Broker)

Ā 

+44 (0) 20 7720 0500

Stephen Keys / George Lawson / Joe SmithĀ (Corporate Finance)

Michael Johnson (Sales)

Ā 

Ā 

AboutĀ Venture LifeĀ (www.venture-life.com)

Venture LifeĀ is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in theĀ UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, EarolĀ® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In theĀ UK, IrelandĀ and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.Ā 

Ā 

The Company makes the following disclosure in accordance with article 19(3) of the Market Abuse Regulation:

1

Ā 

Details of the person discharging managerial responsibilities / person closely associated

Ā 

a)

Ā 

Name

Ā 

Paul McGreevy

2

Ā 

Reason for the notification

Ā 

a)

Ā 

Position/status

Ā 

Non-Executive Chairman

b)

Ā 

Initial notification /Amendment

Ā 

Initial notification

3

Ā 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Ā 

a)

Ā 

Name

Ā 

Venture Life Group plc

b)

Ā 

LEI

Ā 

213800S8CZUPLAB2KC70

4

Ā 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Ā 

a)

Ā 

Description of the financial instrument, type of instrument

Ā 

Ā 

Identification code

Ā 

Ordinary Shares of 0.3p each in Venture Life Group plc

Ā 

Ā 

Ā 

GB00BFPM8908

b)

Ā 

Nature of the transaction

Ā 

Purchase of Ordinary Shares

c)

Ā 

Price(s) and volume(s)

Ā 

Ā 

Ā 

Price

Volume

61.6 pence

8,105

61.9 pence

8,066

61.9 pence

8,066

63.8 pence

15,663

62.0 pence

48,373

d)

Ā 

Aggregated information

Ā 

- Aggregated volume

Ā 

- Price

Ā 

88,273 Ordinary Shares purchased at a volume-weighted average price of 62.3 pence.

Ā 

Ā 

e)

Ā 

Date of the transaction

Ā 

3 June 2026

f)

Ā 

Place of the transaction

Ā 

London Stock Exchange

Ā 

Ā 

Ā 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Ā 
END
Ā 
Ā 
DSHFFFVLRAIVIIR
Date   Source Headline
4th Jun 20267:00 amRNSDirector/PDMR Shareholding
3rd Jun 20267:00 amRNSAcquisition of FemiClear and CUROXEN
1st May 20262:39 pmRNSHolding(s) in Company
1st Apr 20264:30 pmRNSTotal Voting Rights
31st Mar 20267:01 amRNSTransaction in Own Shares
31st Mar 20267:00 amRNSInterim Results
30th Mar 20267:00 amRNSTransaction in Own Shares
27th Mar 20267:00 amRNSTransaction in Own Shares
26th Mar 20269:33 amRNSInvestor Presentation via Investor Meet Company
26th Mar 20267:00 amRNSTransaction in Own Shares
25th Mar 20267:00 amRNSTransaction in Own Shares
24th Mar 20267:00 amRNSTransaction in Own Shares
23rd Mar 20267:00 amRNSTransaction in Own Shares
20th Mar 20267:00 amRNSTransaction in Own Shares
19th Mar 20267:00 amRNSTransaction in Own Shares
18th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
12th Mar 20262:11 pmRNSGrant of Options and Director Dealing
12th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSTransaction in Own Shares
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20264:31 pmRNSTotal Voting Rights
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:00 amRNSTransaction in Own Shares
25th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20267:00 amRNSTransaction in Own Shares
20th Feb 20267:00 amRNSTransaction in Own Shares
18th Feb 20267:00 amRNSTransaction in Own Shares
17th Feb 20267:00 amRNSTransaction in Own Shares
16th Feb 20267:00 amRNSTransaction in Own Shares
13th Feb 20263:07 pmRNSHolding(s) in Company
13th Feb 20267:00 amRNSTransaction in Own Shares
12th Feb 20265:40 pmRNSPCA Dealing
12th Feb 20267:00 amRNSTransaction in Own Shares
6th Feb 20267:00 amRNSTransaction in Own Shares
5th Feb 20267:00 amRNSTransaction in Own Shares
4th Feb 20267:00 amRNSTransaction in Own Shares
3rd Feb 20267:00 amRNSTransaction in Own Shares
2nd Feb 20264:30 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.